Kim Helen Susan
- SEC CIK
- 0001422772
In the past year, 1 open-market purchase filing worth $15.0M and no sales.
Current role at each company
- AKTS Aktis Oncology, Inc.Director, 10% Owneras of Jan 12, 2026
- PRTA Prothena Corp Public Ltd CoDirectoras of May 16, 2025
- AMTI Applied Molecular Transport Inc.Directoras of Aug 27, 2021
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- $15.0M
- 1 filing
- Sold
- –
- 0 filings
- Net
- +$15.0M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Kim Helen Susan as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
AKTS Aktis Oncology, Inc.
Director, 10% Owner1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 12, 2026 (view filing) | Jan 12 | Same day | Kim Helen SusanDirector, 10% Owner | PPurchase | +835.0K | $18.00 | +$15.0M | New position157.4K after | 2 lots |
AMTI Applied Molecular Transport Inc.
Director3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 27, 2021 (view filing) | Aug 26-27 | 1 day | Kim Helen SusanDirector | SSale | −15.0K | $30.20 | −$453.5K | −2.5%575.0K after | 4 lots |
| Aug 25, 2021 (view filing) | Aug 24-25 | 1 day | Kim Helen SusanDirector | SSale | −9.99K | $30.08 | −$300.4K | −1.7%590.0K after | 3 lots |
| Jul 6, 2021 (view filing) | Jul 2 | 4 days | Kim Helen SusanDirector | SSale | −200.0K | $43.32 | −$8.66M | −25.0%600.0K after | 2 lots |